FMP
89bio, Inc.
ETNB
NASDAQ
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
6.75 USD
0.17 (2.52%)
2023
2022
2021
2020
0
0
0
0
273k
240k
79k
60k
-273k
-240k
-79k
-60k
151.2M
102.25M
89.74M
49.35M
122.23M
80.8M
70.33M
36.2M
28.97M
21.45M
19.41M
13.16M
0
0
0
0
28.97M
21.45M
19.41M
13.16M
0
242k
-526k
-203k
-151.2M
102.25M
-89.74M
-49.35M
12.88M
242k
-526k
-203k
-138.32M
-102.01M
-90.27M
-49.56M
3.87M
19k
-147k
-59k
-142.19M
-102.03M
-90.12M
-49.5M
-2
-2.93
-4.48
-3.08
-2
-2.93
-4.48
-3.08
71.17M
34.81M
20.1M
16.09M
71.17M
34.81M
20.1M
16.09M
-134.46M
-99.84M
-90.19M
-49.5M
2023
2022
2021
2020
-315.24M
-213.22M
-123.09M
-73.6M
-142.19M
-102.03M
-90.12M
-49.5M
268k
0
0
0
0
0
0
0
-457.43M
-315.24M
-213.22M
-123.09M
-141.92M
-102.03M
-90.12M
-49.5M
2023
2022
2021
2020
2.34M
455k
150k
166k
273k
240k
79k
60k
-4k
-7k
-63k
-126k
2.07M
222k
134k
232k
2023
2022
2021
2020
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.